247 related articles for article (PubMed ID: 15918196)
1. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia.
Fock KM; Teo EK; Ang TL; Chua TS; Ng TM; Tan YL
World J Gastroenterol; 2005 May; 11(20):3091-8. PubMed ID: 15918196
[TBL] [Abstract][Full Text] [Related]
2. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
Farley A; Wruble LD; Humphries TJ
Am J Gastroenterol; 2000 Aug; 95(8):1894-9. PubMed ID: 10950032
[TBL] [Abstract][Full Text] [Related]
3. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
Robinson M; Fitzgerald S; Hegedus R; Murthy A; Jokubaitis L;
Aliment Pharmacol Ther; 2002 Mar; 16(3):445-54. PubMed ID: 11876697
[TBL] [Abstract][Full Text] [Related]
4. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
Dekkers CP; Beker JA; Thjodleifsson B; Gabryelewicz A; Bell NE; Humphries TJ
Aliment Pharmacol Ther; 1999 Jan; 13(1):49-57. PubMed ID: 9892879
[TBL] [Abstract][Full Text] [Related]
5. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.
Miner P; Orr W; Filippone J; Jokubaitis L; Sloan S
Am J Gastroenterol; 2002 Jun; 97(6):1332-9. PubMed ID: 12094846
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg.
Eggleston A; Katelaris PH; Nandurkar S; Thorpe P; Holtmann G;
Aliment Pharmacol Ther; 2009 May; 29(9):967-78. PubMed ID: 19210493
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.
Holtmann G; Bytzer P; Metz M; Loeffler V; Blum AL
Aliment Pharmacol Ther; 2002 Mar; 16(3):479-85. PubMed ID: 11876701
[TBL] [Abstract][Full Text] [Related]
8. 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms.
Gillessen A; Beil W; Modlin IM; Gatz G; Hole U
J Clin Gastroenterol; 2004 Apr; 38(4):332-40. PubMed ID: 15087692
[TBL] [Abstract][Full Text] [Related]
9. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease.
Delchier JC; Cohen G; Humphries TJ
Scand J Gastroenterol; 2000 Dec; 35(12):1245-50. PubMed ID: 11199361
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.
Miwa H; Sasaki M; Furuta T; Koike T; Habu Y; Ito M; Fujiwara Y; Wada T; Nagahara A; Hongo M; Chiba T; Kinoshita Y;
Aliment Pharmacol Ther; 2007 Jul; 26(1):69-77. PubMed ID: 17555423
[TBL] [Abstract][Full Text] [Related]
11. A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease.
Kobeissy AA; Hashash JG; Jamali FR; Skoury AM; Haddad R; El-Samad S; Ladki R; Aswad R; Soweid AM
World J Gastroenterol; 2012 May; 18(19):2390-5. PubMed ID: 22654431
[TBL] [Abstract][Full Text] [Related]
12. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms.
Moraes-Filho JP; Pedroso M; Quigley EM;
Aliment Pharmacol Ther; 2014 Jan; 39(1):47-56. PubMed ID: 24299323
[TBL] [Abstract][Full Text] [Related]
13. [Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors].
Morozov SV; Tsodikova OM; Isakov VA; Gushchin AE; Shipulin GA
Eksp Klin Gastroenterol; 2003; (6):58-63, 154. PubMed ID: 15065530
[TBL] [Abstract][Full Text] [Related]
14. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease.
Kinoshita Y; Ashida K; Hongo M;
Aliment Pharmacol Ther; 2011 Jan; 33(2):213-24. PubMed ID: 21083596
[TBL] [Abstract][Full Text] [Related]
15. Acid-suppressive effect of rabeprazole 5 mg and 10 mg once daily by 24-hour esophageal pH monitoring in patients with non-erosive reflux disease in Japan: a multicenter, randomized, parallel-group, double-blind pharmacodynamic study.
Ashida K; Kinoshita Y; Hongo M;
Dig Dis Sci; 2011 Aug; 56(8):2333-42. PubMed ID: 21302138
[TBL] [Abstract][Full Text] [Related]
16. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.
Laine L; Katz PO; Johnson DA; Ibegbu I; Goldstein MJ; Chou C; Rossiter G; Lu Y
Aliment Pharmacol Ther; 2011 Jan; 33(2):203-12. PubMed ID: 21114792
[TBL] [Abstract][Full Text] [Related]
17. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
Caos A; Breiter J; Perdomo C; Barth J
Aliment Pharmacol Ther; 2005 Aug; 22(3):193-202. PubMed ID: 16091056
[TBL] [Abstract][Full Text] [Related]
18. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease.
Kahrilas PJ; Miner P; Johanson J; Mao L; Jokubaitis L; Sloan S
Dig Dis Sci; 2005 Nov; 50(11):2009-18. PubMed ID: 16240208
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.
Thjodleifsson B; Rindi G; Fiocca R; Humphries TJ; Morocutti A; Miller N; Bardhan KD;
Aliment Pharmacol Ther; 2003 Feb; 17(3):343-51. PubMed ID: 12562446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
